SSR181507, a putative atypical antipsychotic with dopamine D2 antagonist and 5-HT1A agonist activities: improvement of social interaction deficits induced by phencyclidine in rats
- 20 March 2004
- journal article
- Published by Elsevier in Neuropharmacology
- Vol. 46 (8) , 1121-1129
- https://doi.org/10.1016/j.neuropharm.2004.02.008
Abstract
No abstract availableKeywords
This publication has 38 references indexed in Scilit:
- SSR181507, A Dopamine D2 Receptor Antagonist and 5-HT1A Receptor Agonist. I: Neurochemical and Electrophysiological ProfileNeuropsychopharmacology, 2003
- SSR181507, A Dopamine D2 Receptor Antagonist and 5-HT1A Receptor Agonist. II: Behavioral Profile Predictive of an Atypical Antipsychotic ActivityNeuropsychopharmacology, 2003
- Morphology of the ventral frontal cortex in schizophrenia: relationship with social dysfunctionBiological Psychiatry, 2002
- Relationship of the Use of Adjunctive Pharmacological Agents to Symptoms and Level of Function in SchizophreniaAmerican Journal of Psychiatry, 2002
- Diagnosis and Treatment of Mood Disorders That Co-occur With SchizophreniaPsychiatric Services, 2001
- The use of atypical antipsychotics in the management of schizophreniaBritish Journal of Clinical Pharmacology, 1999
- Neurocognitive deficits and social functioning in outpatients with schizophreniaSchizophrenia Research, 1996
- Low but not high doses of buspirone reduce the anxiogenic effects of diazepam withdrawalPsychopharmacology, 1991
- Positive and Negative Symptoms in SchizophreniaArchives of General Psychiatry, 1990
- CAN SOCIAL INTERACTION BE USED TO MEASURE ANXIETY?British Journal of Pharmacology, 1978